A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene
Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Inclusion Criteria

- Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working
Group (IMWG) criteria.

- Received at least 3 classes of MM treatment [including immunomodulatory drug (IMiD),
proteasome inhibitor (PI), anti CD38 mAb, and at least 3 prior lines of therapy
(LOT).

- Documented disease progression during or after their last anti-myeloma regimen as
per IMWG 2016 criteria.

- Participants must have measurable disease during screening.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria

- Active or history of central nervous system involvement with MM.

- Active systemic fungal, bacterial, viral, or other infection despite appropriate
anti-infective treatment at the time of leukapheresis.

- Received any prior therapy directed at G protein-coupled receptor class C, group 5,
member D (GPRC5D) or has received other prior treatment for MM without the required
washout prior to leukapheresis.

- Other protocol-defined Inclusion/Exclusion criteria apply.